Home > Insider Trading > Filing (0001177648-19-000007)

Filing Details

Accession Number:: 0001177648-19-000007
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-02-13 21:11:31
Reporting Period:: 2019-02-11

Accepted Time:: 2019-02-13 21:11:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1571212	Sun Yat Or	C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472	Sr. Vp & Cso	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-02-11	10,249	$11.77	320,169	No	4	M	Direct
Common Stock	Acquisiton	2019-02-11	6,956	$14.00	327,125	No	4	M	Direct
Common Stock	Acquisiton	2019-02-11	8,772	$14.18	335,897	No	4	M	Direct
Common Stock	Disposition	2019-02-11	5,835	$88.66	330,062	No	4	S	Direct
Common Stock	Disposition	2019-02-11	18,971	$89.50	311,091	No	4	S	Direct
Common Stock	Disposition	2019-02-11	2,707	$90.11	308,384	No	4	S	Direct
Common Stock	Disposition	2019-02-11	171	$91.24	308,213	No	4	S	Direct
Common Stock	Disposition	2019-02-12	6,297	$90.07	301,916	No	4	S	Direct
Common Stock	Acquisiton	2019-02-12	4,500	$0.00	306,416	No	4	A	Direct
Common Stock	Acquisiton	2019-02-12	11,250	$0.00	317,666	No	4	A	Direct
Common Stock	Disposition	2019-02-12	6,993	$88.88	310,673	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Direct
No	4	A	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2019-02-11	10,249	$0.00	10,249	$11.77
Common Stock	Stock Option (Right to Buy)	Disposition	2019-02-11	6,956	$0.00	6,956	$14.00
Common Stock	Stock Option (Right to Buy)	Disposition	2019-02-11	8,772	$0.00	8,772	$14.18

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,672	2022-06-20	No	4	M	Direct
13,926	2023-03-20	No	4	M	Direct
5,149	2022-12-26	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2016
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $88.08 to $88.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $89.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.785, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $91.16 to $91.35, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.13, inclusive.
Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019.
Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019.
Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
100% of the shares subject to the option are fully vested and exercisable.
The option, representing a right to purchase 41,763 shares of common stock, became or will become exercisable in up to nine installments, six of which are installments of 8.33% of the shares and three of which are installments of 16.67% of the shares, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress to clinical development. As of the date of this filing, a total of 50% of the shares subject to the option have become exercisable.